Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2020

May 14, 2020

SELL
$1.9 - $4.98 $67,809 - $177,731
-35,689 Closed
0 $0
Q4 2019

Feb 05, 2020

SELL
$3.95 - $5.35 $140,971 - $190,936
-35,689 Reduced 50.0%
35,689 $168,000
Q4 2019

Feb 05, 2020

BUY
$3.95 - $5.35 $111,291 - $150,736
28,175 Added 65.22%
71,378 $336,000
Q3 2019

Nov 01, 2019

SELL
$4.13 - $6.94 $365,971 - $614,974
-88,613 Reduced 67.22%
43,203 $185,000
Q2 2019

Jul 29, 2019

SELL
$3.98 - $6.2 $212,814 - $331,520
-53,471 Reduced 28.86%
131,816 $768,000
Q1 2019

May 07, 2019

SELL
$2.0 - $4.4 $436,726 - $960,797
-218,363 Reduced 54.1%
185,287 $713,000
Q4 2018

Feb 13, 2019

BUY
$1.61 - $3.62 $649,876 - $1.46 Million
403,650 New
403,650 $755,000

Others Institutions Holding TCRT

About Alaunos Therapeutics, Inc.


  • Ticker TCRT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,182,000
  • Market Cap $443M
  • Description
  • Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...
More about TCRT
Track This Portfolio

Track Ibex Investors LLC Portfolio

Follow Ibex Investors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ibex Investors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ibex Investors LLC with notifications on news.